ID: ALA3618284

Max Phase: Preclinical

Molecular Formula: C19H16N2O2S

Molecular Weight: 336.42

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(=O)C1=C(C)N=C2Sc3ccccc3N2C1c1ccccc1O

Standard InChI:  InChI=1S/C19H16N2O2S/c1-11-17(12(2)22)18(13-7-3-5-9-15(13)23)21-14-8-4-6-10-16(14)24-19(21)20-11/h3-10,18,23H,1-2H3

Standard InChI Key:  BHJMUKWVLJGTKR-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 336.42

Molecular Weight (Monoisotopic): 336.0932

AlogP: 4.28

#Rotatable Bonds: 2

Polar Surface Area: 52.90

Molecular Species: NEUTRAL

HBA: 5

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 9.15

CX Basic pKa: 1.38

CX LogP: 3.84

CX LogD: 3.84

Aromatic Rings: 2

Heavy Atoms: 24

QED Weighted: 0.89

Np Likeness Score: -0.73

References

1. Chikhale R, Thorat S, Pant A, Jadhav A, Thatipamula KC, Bansode R, Bhargavi G, Karodia N, Rajasekharan MV, Paradkar A, Khedekar P..  (2015)  Design, synthesis and pharmacological evaluation of pyrimidobenzothiazole-3-carboxylate derivatives as selective L-type calcium channel blockers.,  23  (20): [PMID:26385444] [10.1016/j.bmc.2015.09.009]

Source

Source(1):

• Scientific Literature